Skip to content
Get Claritide

Not A Peptide, Not A GLP-1

Tesofensine

Also known as NS2330 · Tesomet · Nupenta

Prescription-class · no approved product existsSummary coverage

At a glance

What it is
An oral CNS triple reuptake inhibitor sold through peptide vendors.
Evidence
Small human studiesHow the tiers workPhase 2 data reports roughly 9.2% placebo-subtracted weight loss at 0.5 mg and 6.5% at 0.25 mg over 24 weeks, with a 1.0 mg arm dropped for cardiovascular concerns. Why this tier
Half-life
Approximately 9 days, so it accumulates to steady state over 4–6 weeks.
Routes
Oral
Category
Metabolic
FDA
Investigational
As of 3 August 2026. What that means
WADA
We do not state a status

Putting Tesofensine on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.

Evidence

Why this tier

Phase 2 data reports roughly 9.2% placebo-subtracted weight loss at 0.5 mg and 6.5% at 0.25 mg over 24 weeks, with a 1.0 mg arm dropped for cardiovascular concerns. It is not FDA-approved and no US Phase 3 was running as of April 2026. Sources conflict on its status in Mexico: one states approval since 2023 as Tesomet or Nupenta, another dated June 2026 states that Mexican approval is still pending. We report both rather than picking one.

Overview

What it is

Tesofensine is an oral triple monoamine reuptake inhibitor: serotonin, noradrenaline and dopamine. It is not a peptide and it is not a GLP-1. It is sold through peptide vendors and discussed in peptide forums, and shelving a CNS stimulant-class drug next to BPC-157 is actively dangerous, which is the reason it has a record here.

Mechanism

How it works

Tesofensine blocks the reuptake transporters for serotonin, noradrenaline and dopamine, raising synaptic levels of all three. Appetite suppression follows from that central monoamine elevation rather than from any gut hormone pathway. The same mechanism is why it raises blood pressure and heart rate, why insomnia and mood changes appear over months of use, and why it interacts dangerously with other serotonergic drugs and with MAOIs. Its half-life of around nine days means it accumulates for four to six weeks before reaching steady state, so the full effect, and the full side-effect load, arrive long after the first dose.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.
  • Phase 2 doses0.25–0.5 mg

    Once daily

    Phase 2 reported about 9.2% placebo-subtracted weight loss at 0.5 mg and 6.5% at 0.25 mg over 24 weeks. Investigational: there is no approved US regimen.

Cycle guidance
Not established in available literature
Goals
Fat loss
Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.
Investigationalas of 3 August 2026 · US

Not FDA-approved, with no US Phase 3 running as of April 2026. Sources conflict on Mexico: one reports approval since 2023 as Tesomet or Nupenta, another dated June 2026 reports approval as still pending. We publish the conflict rather than resolving it.

Primary source
Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.
We do not state a status

Not named on the 2026 Prohibited List under a name we could match. Note that stimulants as a class attract attention in anti-doping; we could not determine a classification and do not state one.

We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.

Reconstitution

There is nothing to mix

Not applicable. None of the published routes for this compound take a diluent, so there is no concentration to calculate and no beyond-use window to track.

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.

Not established in available literature.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Common

  • Dry mouth
  • Headache
  • Nausea
  • InsomniaReported over 24 weeks of use.
  • Constipation and diarrhoea
  • Blood pressure and heart rate increaseBlood pressure up 1–3 mmHg and heart rate up to 8 bpm. A 1.0 mg dose arm was dropped from the programme for cardiovascular concerns.

Uncommon

  • Depressed moodReported over 24 weeks of use.
Safety

Contraindications and interactions

Do not use if

  • Uncontrolled hypertension
  • Active psychiatric disease
  • MAOI use
  • Any serotonergic medication: combination risk
  • Pregnancy and adolescence: both excluded from the trials

Interactions

  • MAOIsavoid

    Monoamine reuptake inhibition on top of monoamine oxidase inhibition. Avoid.

  • SSRIs, SNRIs and other serotonergic drugsavoid

    Additive serotonergic load with a nine-day half-life behind it.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage
An oral tablet. There is no diluent, concentration or beyond-use window to track.
Cost
Not established in available literature
Deep dive

Tesofensine in full

Limited coverage, and a warning about shelving

Tesofensine is not a peptide. It is an oral small molecule that blocks the reuptake transporters for serotonin, noradrenaline and dopamine, a triple monoamine reuptake inhibitor, pharmacologically closer to a stimulant antidepressant than to anything else in this library.

It is in this library because it is sold through peptide vendors and discussed in peptide forums, and because a compound with this interaction profile sitting on a shelf next to BPC-157 invites someone to treat it like BPC-157.

What is known

Phase 2 reported roughly 9.2% placebo-subtracted weight loss at 0.5 mg and 6.5% at 0.25 mg over 24 weeks. A 1.0 mg arm was dropped for cardiovascular concerns.

Half-life is about nine days. That is unusual and it matters: the drug accumulates for four to six weeks before it reaches steady state, so the effect you feel in week one is not the effect you will have in week six, and stopping does not clear it quickly either.

Reported adverse effects: dry mouth, headache, nausea, insomnia, diarrhoea, constipation, blood pressure up 1 to 3 mmHg and heart rate up as much as 8 bpm, with insomnia and depressed mood reported across 24 weeks.

Contraindications the trials used

Uncontrolled hypertension, active psychiatric disease, MAOI use, serotonergic combinations. Pregnancy and adolescents were excluded from the trials.

Those are not peptide-style cautions. They are the exclusion criteria of a central nervous system drug, and they should be read as such.

Regulatory conflict, reported as a conflict

Not FDA-approved, with no US Phase 3 running as of April 2026. On Mexico, one source states approval since 2023 as Tesomet or Nupenta; another, dated June 2026, states approval is still pending. We do not know which is right, and we would rather say so than pick.

References

Sources

  1. 1
    Saniona · tesofensine pipeline entry
    Source
  2. 2
    Peptide Dosing Protocols · tesofensine (vendor tier)
    Source
  3. 3
    Genemedics · tesofensine (vendor tier)
    Source

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.